Exploring New Insights into the Future of HSCT and Cellular Therapy AUGUST 31(Thu) - SEPTEMBER 2(Sat), 2023 BUSAN, KOREA / OFFLINE CONGRESS http://icbmt.or.kr

Name	Dr. Katarina Le Blanc	
Current Position	Professor of Clinical Stem Cell Research at Karolinska Institute	16.
Country	Sweden	
Major Field	Dr Le Blanc's main research interest is mesenchymal stem cells, haematopoietic stem cell transplantation and immunology.	

Educational Background

- 2006-11-13 Professor of Clinical Stem Cell Research
- 2004-06-02 Associate Professor (docent) in Hematology, Karolinska Institutet
- 2002 Certified Specialist in Hematology
- 1999-05-10 ECFMG Certificate (American Medical License)
- 1997 Swedish Medical License
- 1993 MD, Karolinska Institutet, Stockholm, Sweden

## **Professional Experience**

2007 - Professor of Clinical Stem Cell Research, Karolinska Institutet

2007–2018 Senior Consultant, Hematology Center, Karolinska University Hospital Huddinge

2019 - present Senior Consultant, Patient Area Cell Therapies and Allogeneic Stem Cell

Transplantation, Karolinska University Hospital, Huddinge

## Other Experience and Professional Memberships

Dr Le Blanc is a member of several international and national committees including notably the Nobel Assembly at Karolinska Institutet and The Royal Swedish Academy of Science. Dr Le Blanc is Ordinary Member of the Pontifical Academy of Life, In the Vatican City State, Rome, Italy.

She is the recipient of several awards including the Knut & Alice Wallenberg Foundation award for young female researchers, Swedish Medical Society award for young scientists, and the Tobias Foundation Prize for the excellent studies of the immunological properties of mesenchymal stem cells and their use in mesenchymal stem cell therapy awarded by the Royal Swedish Academy of Science.

## **Main Scientific Publications**

- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Deans R, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315-317. Cited 11 104 times.
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler M, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graftversus-host disease: a phase II study. Lancet. 2008; 371: 1579-1586. Cited 1980 times.
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 2004; 363: 1439-1441. Cited 2 051 times.